Table of Contents
Abbott completed its acquisition of Exact Sciences on March 23, 2026, making Exact Sciences a wholly owned subsidiary. March 20 was the last day of trading for Exact Sciences shares on the Nasdaq Stock Market.
The acquisition adds a new diagnostics growth vertical for Abbott in cancer screening and precision oncology. It also expands Abbott’s position in what the company describes as a $60 billion U.S. cancer screening and precision oncology diagnostics market, extending its reach in an area tied to rising global cancer incidence.
Before closing, Abbott said the transaction was expected to add approximately $3 billion in incremental 2026 sales, increase 2026 sales growth by about 0.5%, and dilute adjusted 2026 earnings per share by about $0.20.
The acquired portfolio includes Cologuard, Oncotype DX, Oncodetect, and Cancerguard. Abbott said the combined platform supports earlier cancer detection, treatment decision support, and disease monitoring.
Comments